ALPHARETTA, GA / ACCESSWIRE / July 15, 2021 / RushNet, Inc. (OTC PINK:RSHN), ("the Company") is pleased to announce the first Board Member of heliosDX upon the Split-Off of RushNet, Inc.
Our first Board Member is Mr. Scott Wakeman. Mr. Wakeman currently serves as the Executive Vice President of Operations for Edible Arrangements, where he oversees Store Operations, Customer Service, and Development/Training. Prior to his current position, he managed Marketing, Field Marketing and Creative Services for Edible as Executive Vice President of Marketing.
Before joining Edible in 2019, Scott held a variety of senior marketing roles including Vice President of Marketing at Checkers and Rally's, Head of Marketing and Broadcast for the Houston Astros and Group Vice President at Grey Advertising. Mr. Wakeman began his career in packaged goods and has served in general management roles at several Fortune 500 companies, including Colgate-Palmolive, L'Oréal and Bacardi. Mr. Wakeman is an alumnus of Emory University where he received a Bachelor of Arts degree with honors in Political Science and captained the varsity basketball team. He also received an MBA from Duke University. You can view Mr. Wakeman's linked in profile by Clicking Here.
heliosDX feels extremely fortunate to be able to add such talent to its Board of Directors. The company recently finished its Phase One rebranding strategy from Chattahoochee Labs to heliosDX. The company is preparing to launch a national sales campaign in the coming weeks to further its already rapidly increasing footprint. The campaign is designed to accomplish two goals. The first goal is to grow our sales reach and gain incremental new business across the country. The second goal is to utilize the national sales campaign as a mechanism of pushing the heliosDX brand further, in what we are calling Phase Two. heliosDX believes Mr. Wakeman's experience in senior leadership with marketing and operation roles brings many synergies with the national branding and marketing efforts currently ongoing. Mr. Wakeman will be a vital asset serving in an advisement capacity to heliosdX as we continue to create brand awareness nationwide.
heliosDX was recently acquired by RushNet, Inc, which was the first milestone for heliosDX realizing its goal to becoming a fully reporting standalone company trading under its own symbol. The company is currently preparing its applications for FINRA, SEC and disclosures.
heliosDX previously announced there will be a dividend of 1 share of heliosDX for every 800 shares of RushNet owned upon close of the ex-dividend date. RushNet shareholders have access to purchase 11 additional shares of heliosDX per 1,000 shares of Rushnet, Inc at a 50% to market upon the close on the ex-dividend date. For every 10 shares purchased at the discount to market of 50% the shareholder receives one additional share of heliosDX.
heliosDX would like to formally announce it will also include the ability to convert qualified shares of Rushnet into heliosDX upon the split-off. A qualified share of RushNet is a share owned on the close of the ex-dividend date. The conversion ratio is yet to be determine but is customarily done at an equal value with an incentive percentage to convert. The incentive percentage has not been determined but will not be less than 10%.
heliosDX believes this provides a unique opportunity to bring considerable value to RushNet shareholders and has significant impact on lowering the Share Structure of RushNet, Inc upon split-off. The ex-dividend has not been determined. There will be additional information released in the near-term regarding the ex-dividend date and qualification guidelines.
heliosDX is a National Clinical Reference Laboratory offering High-Complexity Urine Drug Testing (UDT), Behavioral Drug Testing, Allergy Droplet Cards, Oral Fluids, Infectious Disease (PCR), and NGS Genetic Testing. We are contracted in 44 of the lower 48 states and looking to expand our reach and capabilities. Always staying ahead of the curve, by continually investing in our infrastructure with the most efficient scientific proven instruments, and latest cutting-edge software for patient and physician satisfaction. This allows heliosDX to provide physicians fast and accurate reporting meeting and exceeding industry benchmarks. We excel in patient and client care through physician designed panels that aid in testing compliance and reporting education.
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Companies caution that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. The Companies undertake no obligation to revise these statements following the date of this news release.
Investor caution/added risk for investors in companies claiming involvement in COVID-19 initiatives -
On April 8, 2020, SEC Chairman Jay Clayton and William Hinman, the Director of the Division of Corporation Finance, issued a joint public statement on the importance of disclosure during the COVID-19 crisis.
The SEC and Self-Regulatory Organizations are targeting public companies that claim to have products, treatment, or other strategies with regard to COVID-19.
The ultimate impact of the COVID-19 pandemic on the Company's operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak. Additionally, new information may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time.
We further caution investors that our primary focus and goal is to battle this pandemic for the good of the world. As such, it is possible that we may find it necessary to make disclosures which are consistent with that goal, but which may be adverse to the pecuniary interests of the Company and of its shareholders.
SOURCE: RushNet, Inc.
View source version on accesswire.com:
© 2021 Accesswire. All Rights Reserved.